4.8 Article

Single Mutation on Trastuzumab Modulates the Stability of Antibody-Drug Conjugates Built Using Acetal-Based Linkers and Thiol-Maleimide Chemistry

Journal

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
Volume 144, Issue 12, Pages 5284-5294

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/jacs.1c07675

Keywords

-

Funding

  1. Agencia Estatal Investigacion of Spain (AEI) [RTI2018-099592-B-C21, RTI2018-099592B-C22]
  2. European Union [675007]
  3. Universidad de la Rioja
  4. Ministerio de Universidades of Spain [BG20/00103]
  5. Xunta da Galicia [I2C-ED481B 2014/086-0, ED481B 2018/007]
  6. Schmidt Science Fellowship program
  7. MINECO [PRE2018-085973]
  8. Agencia Estatal de Investigacion for the Severo Ochoa Excellence Accreditation to CIC bioGUNE [SEV-2016-0644]
  9. Marie Curie Actions (MSCA) [675007] Funding Source: Marie Curie Actions (MSCA)

Ask authors/readers for more resources

Antibody-drug conjugates (ADCs) are targeted therapeutics used to kill cancer cells. This study investigates the influence of the site and microenvironment of the trastuzumab antibody on the stability of the conjugation and linkers. The study found that the chemical environment of the conjugation site plays a key role in the stability, and mutation or using longer linkers can enhance stability.
Antibody-drug conjugates (ADCs) are a class of targeted therapeutics used to selectively kill cancer cells. It is important that they remain intact in the bloodstream and release their payload in the target cancer cell for maximum efficacy and minimum toxicity. The development of effective ADCs requires the study of factors that can alter the stability of these therapeutics at the atomic level. Here, we present a general strategy that combines synthesis, bioconjugation, linker technology, site-directed mutagenesis, and modeling to investigate the influence of the site and microenvironment of the trastuzumab antibody on the stability of the conjugation and linkers. Trastuzumab is widely used to produce targeted ADCs because it can target with high specificity a receptor that is overexpressed in certain breast cancer cells (HER2). We show that the chemical environment of the conjugation site of trastuzumab plays a key role in the stability of linkers featuring acid-sensitive groups such as acetals. More specifically, Lys-207, located near the reactive Cys-205 of a thiomab variant of the antibody, may act as an acid catalyst and promote the hydrolysis of acetals. Mutation of Lys-207 into an alanine or using a longer linker that separates this residue from the acetal group stabilizes the conjugates. Analogously, Lys-207 promotes the beneficial hydrolysis of the succinimide ring when maleimide reagents are used for conjugation, thus stabilizing the subsequent ADCs by impairing the undesired retro-Michael reactions. This work provides new insights for the design of novel ADCs with improved stability properties.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available